Patent intelligence · US
US 9771585
miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
Patent details — US 9771585
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 26, 2017
- Expiration
- Sep 21, 2037
- Applicant
- MIRAGEN THERAPEUTICS, INC.
- Claims
- 12
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P43/00
Quick answer
US 9771585 (miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)) is held by MIRAGEN THERAPEUTICS, INC.. Status: granted. Granted Sep 26, 2017. Expires Sep 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MIRAGEN THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P43/00
More from MIRAGEN THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 9771585?
US 9771585 (miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)) is held by MIRAGEN THERAPEUTICS, INC.. Status: granted. Granted Sep 26, 2017. Expires Sep 21, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9771585?
MIRAGEN THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 9771585 expire?
Our index shows an expiration date of Sep 21, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.